Just Released: "Poland Pharmaceuticals & Healthcare Report Q2 2014"
The Polish national health insurer has updated its reimbursement list, with a mix of positive and negative developments. Generic drugmakers are expected to feel further pricing pressures in 2014, while multinational drugmakers will welcome the decision to improve access to innovative therapies for cancer patients. With among the lowest drug prices in Europe, we expect patented drugs to outperform over the short-term as cost savings from generic drugs are passed onto funding expensive medicines.
View full press release